Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD70 is a type II transmembrane protein belonging to the TNF ligand family. It is transiently expressed on activated T cells, B cells, dendritic cells, and NK cells. CD70 is the ligand for CD27, and their interaction provides costimulatory signals for T-cell and B-cell activation, proliferation, and survival. CD70 is overexpressed in several hematologic malignancies and some solid tumors, promoting cell proliferation and survival and inhibiting apoptosis. Anti-CD70 therapies are being explored as cancer treatments. CD70 also plays a role in transplant immunology and graft-versus-host disease.
Anti-CD70 antibodies inhibit CD70 and prevent its interaction with CD27, thus suppressing T-cell and B-cell activation, proliferation, and survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cluster of Differentiation 70 (CD70).